Clinical effectiveness of the angiotensin converting enzyme inhibitor, Ramipril, in patients with intermittent claudication : randomised, double-blind, placebo-controlled trial
Background: The HOPE trial showed that ramipril reduced cardiovascular morbidity and mortality in patients with peripheral arterial disease (PAD). However, evidence regarding the effect of angiotensin converting enzyme (ACE) inhibitors on walking distance, ankle brachial pressure index (ABPI), arter...
Main Author: | Shahin, Yousef |
---|---|
Published: |
Cardiff University
2015
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.667910 |
Similar Items
-
Haemostatic changes in intermittent claudication
by: Burns, Paul
Published: (2005) -
Free-living physical activity as an outcome measure in individuals with intermittent claudication
by: Clarke, Clare L.
Published: (2013) -
The renin angiotensin aldosterone axis : relationships with other hormone systems, and novel applications for angiotensin converting enzyme inhibitors
by: Lee, Alison Frances Clare
Published: (2000) -
Increasing walking in individuals with intermittent claudication : the roles of walking treatment and illness cognitions
by: Galea Holmes, Melissa
Published: (2016) -
Effect of ramipril on renal function in patients with intermittent claudication
by: Simon D Hobbs, et al.
Published: (2008-04-01)